Skip to main content

Table 2 Clinical characteristics of the nine clusters found in the focused handprint analysis

From: A computational framework for complex disease stratification from multiple large-scale datasets

Variables/clusters

C1 (n = 49)

C2 (n = 30)

C3 (n = 75)

C4 (n = 41)

C5 (n = 47)

C6 (n = 52)

C7 (n = 46)

C8 (n = 56)

C9 (n = 57)

P-value

Age at initial pathologic diagnosis (Yr)

57.6 ± 13.2

53.5 ± 8.16

59.8 ± 10.7

61.1 ± 12

60.2 ± 9.67

63.4 ± 11.8

59.8 ± 12.5

59.4 ± 11.6

60 ± 11.4

3.40E-02 2

Days from birth (Days)

−21,200 ± 4830

−19,700 ± 3030

−21,900 ± 3870

−22,700 ± 4260

−22,200 ± 2580

− 23,300 ± 4290

−22,000 ± 4560

−21,900 ± 4240

−22,200 ± 4140

3.15E-02 2

Days to death (Days (IQR))

1220 (725–1490)

1480 (1210–2360)

997 (404–1230)

949 (563–1360)

787 (512–1340)

1090 (680–1580)

978 (536–1450)

1070 (340–1440)

1290 (731–1700)

2.11E-02 1

Days to last followup (Days (IQR))

1090 (689–1460)

1200 (688–1550)

664 (238–1120)

763 (272–1820)

676 (185–1560)

804 (339–1560)

651 (347–1370)

816 (223–1370)

1280 (605–1690)

3.74E-02 1

Initial pathologic diagnosis method

Cytology: 9; Excisional biopsy: 2; Fine needle aspiration biopsy: 2; Incisional biopsy: 4; Tumor resection: 32

Cytology: 3; Excisional biopsy: 0; Fine needle aspiration biopsy: 0; Incisional biopsy: 0; Tumor resection: 27

Cytology: 12; Excisional biopsy: 0; Fine needle aspiration biopsy: 3; Incisional biopsy: 0; Tumor resection: 59; NA: 1

Cytology: 2; Excisional biopsy: 0; Fine needle aspiration biopsy: 2; Incisional biopsy: 1; Tumor resection: 36

Cytology: 9; Excisional biopsy: 2; Fine needle aspiration biopsy: 0; Incisional biopsy: 2; Tumor resection: 33; NA: 1

Cytology: 6; Excisional biopsy: 0; Fine needle aspiration biopsy: 1; Incisional biopsy: 0; Tumor resection: 44; NA: 1

Cytology: 2; Excisional biopsy: 0; Fine needle aspiration biopsy: 0; Incisional biopsy: 0; Tumor resection: 44

Cytology: 9; Excisional biopsy: 1; Fine needle aspiration biopsy: 0; Incisional biopsy: 3; Tumor resection: 43

Cytology: 5; Excisional biopsy: 0; Fine needle aspiration biopsy: 1; Incisional biopsy: 0; Tumor resection: 51

3.28E-03 3

Lymphatic invasion

No: 4; Yes: 9; NA: 36

No: 6; Yes: 10; NA: 14

No: 7; Yes: 19; NA: 49

No: 13; Yes: 5; NA: 23

No: 1; Yes: 17; NA: 29

No: 13; Yes: 6; NA: 33

No: 8; Yes: 21; NA: 17

No: 4; Yes: 8; NA: 44

No: 5; Yes: 14; NA: 38

2.43E-02 3

Neoplasm histologic grade

G1: 1; G2: 13; G3: 33; G4: 0; Gb: 1; Gx: 1

G1: 0; G2: 5; G3: 24; G4: 0; Gb: 0; Gx: 0; NA: 1

G1: 0; G2: 5; G3: 70; G4: 0; Gb: 0; Gx: 0

G1: 0; G2: 5; G3: 36; G4: 0; Gb: 0; Gx: 0

G1: 0; G2: 6; G3: 39; G4: 0; Gb: 0; Gx: 2

G1: 0; G2: 6; G3: 44; G4: 1; Gb: 0; Gx: 1

G1: 0; G2: 8; G3: 38; G4: 0; Gb: 0; Gx: 0

G1: 0; G2: 1; G3: 53; G4: 0; Gb: 0; Gx: 2

G1: 0; G2: 6; G3: 49; G4: 0; Gb: 0; Gx: 1; NA: 1

1.89E-02 1

Ethnicity

American Indian or Alaska native: 1; Asian: 1; Black or African American: 3; White: 43; NA: 1

American Indian or Alaska native: 0; Asian: 1; Black or African American: 2; White: 27; NA: 0

American Indian or Alaska native: 0; Asian: 3; Black or African American: 2; White: 68; NA: 2

American Indian or Alaska native: 0; Asian: 1; Black or African American: 3; White: 37; NA: 0

American Indian or Alaska native: 1; Asian: 1; Black or African American: 0; White: 41; NA: 4

American Indian or Alaska native: 0; Asian: 2; Black or African American: 4; White: 44; NA: 2

American Indian or Alaska native: 0; Asian: 3; Black or African American: 1; White: 41; NA: 1

American Indian or Alaska native: 0; Asian: 3; Black or African American: 2; White: 49; NA: 2

American Indian or Alaska native: 0; Asian: 0; Black or African American: 4; White: 51; NA: 2

6.72E-01 3

Clinical stage

iia: 0; iib: 0; iic: 0; iiia: 1; iiib: 0; iiic: 38; iv: 10; NA: 0

iia: 0; iib: 0; iic: 1; iiia: 0; iiib: 1; iiic: 24; iv: 3; NA: 1

iia: 0; iib: 0; iic: 3; iiia: 1; iiib: 3; iiic: 51; iv: 16; NA: 1

iia: 0; iib: 0; iic: 3; iiia: 4; iiib: 4; iiic: 22; iv: 7; NA: 1

iia: 0; iib: 1; iic: 1; iiia: 0; iiib: 2; iiic: 33; iv: 9; NA: 1

iia: 0; iib: 0; iic: 2; iiia: 1; iiib: 5; iiic: 38; iv: 6; NA: 0

iia: 1; iib: 1; iic: 2; iiia: 0; iiib: 4; iiic: 34; iv: 4; NA: 0

iia: 0; iib: 0; iic: 1; iiia: 0; iiib: 1; iiic: 42; iv: 12; NA: 0

iia: 2; iib: 2; iic: 4; iiia: 0; iiib: 1; iiic: 41; iv: 7; NA: 0

2.65E-02 1

Tumor residual disease

> 20 mm: 10; 1–10 mm: 26; 11–20 mm: 6; no macroscopic disease: 4; NA: 3

> 20 mm: 5; 1–10 mm: 17; 11–20 mm: 5; no macroscopic disease: 12; NA: 4

> 20 mm: 17; 1–10 mm: 29; 11–20 mm: 5; no macroscopic disease: 12; NA: 12

> 20 mm: 6; 1–10 mm: 18; 11–20 mm: 1; no macroscopic disease: 12; NA: 4

> 20 mm: 11; 1–10 mm: 21; 11–20 mm: 4; no macroscopic disease: 3; NA: 8

> 20 mm: 4; 1–10 mm: 24; 11–20 mm: 5; no macroscopic disease: 12; NA: 7

> 20 mm: 8; 1–10 mm: 15; 11–20 mm: 5; no macroscopic disease: 13; NA: 5

> 20 mm: 6; 1–10 mm: 29; 11–20 mm: 2; no macroscopic disease: 14; NA: 5

> 20 mm: 11; 1–10 mm: 25; 11–20 mm: 2; no macroscopic disease: 14; NA: 5

6.13E-02 1

Tumor tissue site

Omentum: 0; Ovary: 48; Peritoneum ovary: 1

Omentum: 0; Ovary: 30; Peritoneum ovary: 0

Omentum: 1; Ovary: 74; Peritoneum ovary: 0

Omentum: 0; Ovary: 41; Peritoneum ovary: 0

Omentum: 1; Ovary: 46; Peritoneum ovary: 0

Omentum: 0; Ovary: 52; Peritoneum ovary: 0

Omentum: 0; Ovary: 46; Peritoneum ovary: 0

Omentum: 0; Ovary: 56; Peritoneum ovary: 0

Omentum: 0; Ovary: 57; Peritoneum ovary: 0

5.01E-01 3

Venous invasion

No: 3; Yes: 3; NA: 43

No: 3; Yes: 10; NA: 17

No: 8; Yes: 7; NA: 60

No: 12; Yes: 3; NA: 26

No: 1; Yes: 10; NA: 36

No: 10; Yes: 5; NA: 37

No: 7; Yes: 20; NA: 19

No: 3; Yes: 1; NA: 52

No: 3; Yes: 10; NA: 44

7.24E-02 3

Vital status

Alive: 9; Dead: 40, NA: 0

Alive: 14; Dead: 16; NA: 0

Alive: 33; Dead: 42; NA:0

Alive: 18; Dead: 23; NA: 0

Alive: 20; Dead: 27; NA:

Alive: 20; Dead: 31; NA: 1

Alive: 28; Dead: 18; NA: 0

Alive: 31; Dead: 25; NA: 0

Alive: 27; Dead: 30; NA: 0

1.90E-03 3

Primary therapy outcome success

Complete remission/response: 24; Partial remission/response: 12; Progressive disease: 3; Stable disease: 1; NA: 9

Complete remission/response: 17; Partial remission/response: 3; Progressive disease: 4; Stable disease: 2; NA: 4

Complete remission/response: 41; Partial remission/response: 7; Progressive disease: 2; Stable disease: 4; NA: 21

Complete remission/response: 24; Partial remission/response: 4; Progressive disease: 2; Stable disease: 0; NA: 11

Complete remission/response: 24; Partial remission/response: 8; Progressive disease: 4; Stable disease: 3; NA: 8

Complete remission/response: 29; Partial remission/response: 6; Progressive disease: 1; Stable disease: 5; NA: 11

Complete remission/response: 27; Partial remission/response: 5; Progressive disease: 4; Stable disease: 6; NA: 4

Complete remission/response: 36; Partial remission/response: 4; Progressive disease: 7; Stable disease: 2; NA: 7

Complete remission/response: 35; Partial remission/response: 5; Progressive disease: 5; Stable disease: 1; NA: 11

5.08E-01 1

Days lived known

22,300 ± 4750

21,100 ± 3150

22,800 ± 3930

23,800 ± 4050

23,300 ± 3840

24,500 ± 4140

23,000 ± 4490

22,800 ± 4430

23,400 ± 4240

3.85E-02 2

  1. Nominally statistically significant differences (p < 0.05) are shown in italic. Interestingly, significant differences are detected in lymphatic invasion, clinical stage at diagnosis, vital status and the overall number of days alive